BOSTON, March 4, 2025 /PRNewswire/ — Magnet Biomedicine, a biotechnology company advancing molecular glue discovery through rational selection and design, has selected Simplicis’s Ledger™ platform after a rigorous evaluation process that considered several leading competitors. Simplicis’s unmatched combination of innovation, adaptability, and cost-efficiency proved to be the ideal choice to support Magnet’s cutting-edge research operations.
Magnet Biomedicine is recognized for its TrueGlue™ discovery platform, which leverages advancements in human biology and proteomics to develop next-generation molecular glues targeting critical unmet medical needs. Choosing Simplicis’s Ledger™ platform enables Magnet to advance its mission to deliver transformative therapeutic solutions.
Strategic Decision to Partner with Simplicis
Liam Hudson, Associate Director at Magnet Biomedicine, explained the decision-making process:
“After evaluating multiple platforms, it was clear that Simplicis offered a combination of Functionality, technical knowledge and value that others could not match. Ledger™ stood out as the solution that best aligns with our operational needs and future growth.
Hudson also emphasized the importance of collaboration and innovation:
“Simplicis’s pragmatic and forward-thinking approach equips us with the tools to enhance our compound management capabilities and scale efficiently.”
Driving Operational Efficiency with Advanced Technology
Gina Chen, Compound Management Lead at Magnet Biomedicine, highlighted the user-centric design and adaptability of Simplicis’s Ledger™ platform:
“Ledger™ delivers all the features we needed—and more—in a streamlined, user-friendly interface. Its ability to support pre-validation of requests ensures accountability and simplifies workflows across teams.”
Chen also noted the impact of advanced automation on team productivity:
“With Simplicis, we’ve seen a significant reduction in manual tasks, allowing us to focus on the science rather than the logistics.”
Integration and Flexibility as Key Differentiators
James Ralff, Research Associate at Magnet Biomedicine, praised Ledger™ seamless integration capabilities:
“Ledger™ integrates effortlessly with our existing workflows, offering intuitive tools that simplify data management and enable us to work more efficiently.”
Ralff highlighted the platform’s ability to handle complex workflows:
“Simplicis’s capabilities empower us to mine data effectively, streamline plate mapping, and optimize our processes in ways that were previously unattainable.”
Implementation and Looking Ahead
Magnet Biomedicine has already begun its transition to the Ledger™ platform, with a full go-live expected in February 2025. The implementation process includes migrating legacy systems, integrating key hardware, and training staff to leverage the platform’s full potential. The partnership is expected to drive significant operational efficiencies, enhance collaboration, and provide a strong foundation for future growth.
About Magnet Biomedicine
Magnet Biomedicine is a biotechnology company advancing molecular glue discovery through rational selection and design. The company’s TrueGlue™ discovery platform integrates cutting-edge science and technology to develop therapeutic solutions that address critical unmet medical needs, offering transformative potential for precision medicine.
For more information, visit magnetbio.com.
About Simplicis
Simplicis is a leading provider of laboratory information management systems (LIMS) designed to optimize workflows, enhance data management, and drive innovation. The Ledger™ platform is a state-of-the-art solution tailored to meet the evolving needs of the biotechnology and pharmaceutical sectors, delivering efficiency and scalability for research organizations worldwide.
For more information, visit simplicis.com
Media Contact:
Jennifer Franklin
Vice President of Administration & Operations
Magnet Biomedicine
info@magnetbio.com
(617) 741-0974
SOURCE Simplicis
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…
Independent report examines Calm Nature CBD Gummies full spectrum formulation, CO2 extraction claims, THC removal…